Health Care [ 7/12 ] | Biotechnology [ 27/75 ]
NASDAQ | Common Stock
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.
The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 24, 26 | -0.03 Increased by +75.00% | -0.14 Increased by +79.17% |
| Nov 6, 25 | -0.19 Decreased by -11.76% | -0.14 Decreased by -35.71% |
| Aug 7, 25 | -0.12 Increased by +7.69% | -0.14 Increased by +14.29% |
| May 5, 25 | -0.15 Decreased by -7.14% | -0.17 Increased by +11.76% |
| Feb 18, 25 | -0.12 Increased by +29.41% | -0.15 Increased by +18.42% |
| Nov 4, 24 | -0.17 Decreased by -70.00% | -0.15 Decreased by -13.33% |
| Aug 6, 24 | -0.13 Decreased by -18.18% | -0.14 Increased by +7.14% |
| May 7, 24 | -0.14 Increased by 0.00% | -0.17 Increased by +17.65% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 8.96 M Increased by +37.62% | -57.12 M Decreased by -11.76% | Decreased by -637.84% Increased by +18.79% |
| Jun 30, 25 | 17.08 M Increased by +133.29% | -34.73 M Increased by +5.97% | Decreased by -203.27% Increased by +59.69% |
| Mar 31, 25 | 4.24 M Decreased by -57.45% | -45.62 M Decreased by -12.34% | Decreased by -1.08 K% Decreased by -164.04% |
| Dec 31, 24 | 5.05 M Decreased by -44.98% | -34.21 M Increased by +27.44% | Decreased by -677.43% Decreased by -31.88% |
| Sep 30, 24 | 6.51 M Decreased by -1.39% | -51.11 M Decreased by -78.63% | Decreased by -785.42% Decreased by -81.16% |
| Jun 30, 24 | 7.32 M Decreased by -27.18% | -36.93 M Decreased by -20.97% | Decreased by -504.30% Decreased by -66.12% |
| Mar 31, 24 | 9.95 M Decreased by -18.36% | -40.61 M Decreased by -1.25% | Decreased by -407.98% Decreased by -24.01% |
| Dec 31, 23 | 9.18 M Decreased by -57.40% | -47.15 M Decreased by -57.73% | Decreased by -513.67% Decreased by -270.22% |